Skip to content
OpenCapital
Get started

Amgen AMGN TEZSPIRE — Total revenues

Other product segments

Repatha
$3.02B—
Other products
$1.53B+3.6%
Prolia
$727M-33.8%
EVENITY
$562M+27.1%
TEPEZZA
$490M+28.6%
Otezla
$431M-1.4%
BLINCYTO
$415M+12.2%
Nplate
$412M+31.6%
XGEVA
$411M-27.4%
KYPROLIS
$330M+1.9%
ENBREL
$320M-37.3%
Aranesp
$311M-8.5%
Vectibix
$287M+7.5%
UPLIZNA
$262M+188%
IMDELLTRA/IMDYLLTRA
$258M+219%
KRYSTEXXA
$255M+8.1%

Similar metrics at other companies

Biogen logo
BIIBTYSABRI — Total Revenue
$450.8M-0.8%
Gilead Sciences logo
GILDTecartus — Total revenues
$75M-3.8%
Bristol-Myers Squibb logo
BMYSprycel — Total Revenues
$88M-26.7%
Gilead Sciences logo
GILDProduct sales — Total revenues
$6.95B+5.0%
United Therapeutics logo
UTHRTyvaso DPI — Total revenues
$330.3M+9.2%
United Therapeutics logo
UTHRTotal Tyvaso — Total revenues
$457.5M-1.9%

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$212.16B+30.0%
Enterprise value$268.92B+22.9%
P/E27.2×+2.5×
P/S5.7×+1.0×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's tezspire — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's TEZSPIRE — total revenues?
Amgen (AMGN) reported TEZSPIRE — total revenues of $343M in Q1 2026.
How has Amgen's TEZSPIRE — total revenues changed year-over-year?
Amgen's TEZSPIRE — total revenues increased by 20.4% year-over-year, from $285M to $343M.
What is the long-term trend for Amgen's TEZSPIRE — total revenues?
Over 3 years (2022 to 2025), Amgen's TEZSPIRE — total revenues has grown at a 105.6% compound annual growth rate (CAGR), from $170M to $1.48B.
What does TEZSPIRE — total revenues mean?
This metric represents the total gross sales generated by the specific therapeutic product line within the company's portfolio. It reflects the market adoption, pricing power, and clinical demand for this particular pharmaceutical asset. Monitoring this revenue stream helps investors assess the commercial trajectory and growth contribution of the product to the overall corporate top line.